142 related articles for article (PubMed ID: 27259271)
1. Identification of Glypican-3 as a potential metastasis suppressor gene in gastric cancer.
Han S; Ma X; Zhao Y; Zhao H; Batista A; Zhou S; Zhou X; Yang Y; Wang T; Bi J; Xia Z; Bai Z; Garkavtsev I; Zhang Z
Oncotarget; 2016 Jul; 7(28):44406-44416. PubMed ID: 27259271
[TBL] [Abstract][Full Text] [Related]
2. Identification of miR-4510 as a metastasis suppressor of gastric cancer through regulation of tumor microenvironment via targeting GPC3.
Ma HF; Shu P; Shi XH; Wang M; Jiang MF
Clin Exp Metastasis; 2022 Apr; 39(2):363-374. PubMed ID: 35050429
[TBL] [Abstract][Full Text] [Related]
3. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas.
Ushiku T; Uozaki H; Shinozaki A; Ota S; Matsuzaka K; Nomura S; Kaminishi M; Aburatani H; Kodama T; Fukayama M
Cancer Sci; 2009 Apr; 100(4):626-32. PubMed ID: 19243386
[TBL] [Abstract][Full Text] [Related]
4. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.
Castillo LF; Tascón R; Lago Huvelle MR; Novack G; Llorens MC; Dos Santos AF; Shortrede J; Cabanillas AM; Bal de Kier Joffé E; Labriola L; Peters MG
Oncotarget; 2016 Sep; 7(37):60133-60154. PubMed ID: 27507057
[TBL] [Abstract][Full Text] [Related]
6. Targeting GPC3
Li D; Wang Y; Shi C; Fu S; Sun YF; Li C
Ann Med; 2023 Dec; 55(1):2189295. PubMed ID: 37036308
[TBL] [Abstract][Full Text] [Related]
7. Glypican 3 overexpression in primary and metastatic Wilms tumors.
Tretiakova M; Zynger DL; Luan C; Andeen NK; Finn LS; Kocherginsky M; Teh BT; Yang XJ
Virchows Arch; 2015 Jan; 466(1):67-76. PubMed ID: 25366870
[TBL] [Abstract][Full Text] [Related]
8. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 (GPC3) inhibits metastasis development promoting dormancy in breast cancer cells by p38 MAPK pathway activation.
Guereño M; Delgado Pastore M; Lugones AC; Cercato M; Todaro L; Urtreger A; Peters MG
Eur J Cell Biol; 2020 Aug; 99(6):151096. PubMed ID: 32800275
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma.
Deveci MS; Deveci G
Gastric Cancer; 2007; 10(2):112-6. PubMed ID: 17577621
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma.
Hishinuma M; Ohashi KI; Yamauchi N; Kashima T; Uozaki H; Ota S; Kodama T; Aburatani H; Fukayama M
Histopathology; 2006 Nov; 49(5):479-86. PubMed ID: 17064293
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.
Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G
Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
14. Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database.
Moek KL; Fehrmann RSN; van der Vegt B; de Vries EGE; de Groot DJA
Am J Pathol; 2018 Sep; 188(9):1973-1981. PubMed ID: 29935166
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients.
Grillo PK; Győrffy B; Götte M
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1937-1955. PubMed ID: 33742285
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
19. High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Miskad UA; Semba S; Kato H; Matsukawa Y; Kodama Y; Mizuuchi E; Maeda N; Yanagihara K; Yokozaki H
Virchows Arch; 2007 Mar; 450(3):303-10. PubMed ID: 17235563
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
Mounajjed T; Zhang L; Wu TT
Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
